Trial Profile

Time-limited Triplet Combination of Pirtobrutinib, Venetoclax, and Obinutuzumab for Patients With Treatment-naïve Chronic Lymphocytic Leukemia (CLL) or Richter Transformation (RT)

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 17 Apr 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Allopurinol (Primary) ; Obinutuzumab (Primary) ; Pirtobrutinib (Primary) ; Valaciclovir (Primary) ; Venetoclax (Primary)
Indications Chronic lymphocytic leukaemia; Richter's syndrome
Focus Adverse reactions

Most Recent Events

08 Apr 2025 Planned End Date changed from 25 Apr 2025 to 25 Apr 2028.
08 Apr 2025 Planned primary completion date changed from 25 Apr 2025 to 25 Apr 2028.
31 May 2024 According to an Adaptive Biotechnologies media release, data from this trial to be presented at the European Hematology Association (EHA) Hybrid Congress taking place June 13-16 in Madrid and virtually.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com